144 related articles for article (PubMed ID: 35985255)
1. Discovery of novel PDE4 inhibitors targeting the M-pocket from natural mangostanin with improved safety for the treatment of Inflammatory Bowel Diseases.
Liu H; Wang Q; Huang Y; Deng J; Xie X; Zhu J; Yuan Y; He YM; Huang YY; Luo HB; He X
Eur J Med Chem; 2022 Nov; 242():114631. PubMed ID: 35985255
[TBL] [Abstract][Full Text] [Related]
2. Discovery and Optimization of α-Mangostin Derivatives as Novel PDE4 Inhibitors for the Treatment of Vascular Dementia.
Liang J; Huang YY; Zhou Q; Gao Y; Li Z; Wu D; Yu S; Guo L; Chen Z; Huang L; Liang SH; He X; Wu R; Luo HB
J Med Chem; 2020 Mar; 63(6):3370-3380. PubMed ID: 32115956
[TBL] [Abstract][Full Text] [Related]
3. Mangostanin Derivatives as Novel and Orally Active Phosphodiesterase 4 Inhibitors for the Treatment of Idiopathic Pulmonary Fibrosis with Improved Safety.
Huang YY; Deng J; Tian YJ; Liang J; Xie X; Huang Y; Zhu J; Zhu Z; Zhou Q; He X; Luo HB
J Med Chem; 2021 Sep; 64(18):13736-13751. PubMed ID: 34520193
[TBL] [Abstract][Full Text] [Related]
4. PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease.
Banner KH; Trevethick MA
Trends Pharmacol Sci; 2004 Aug; 25(8):430-6. PubMed ID: 15276712
[TBL] [Abstract][Full Text] [Related]
5. The selective phosphodiesterase 4 inhibitor roflumilast and phosphodiesterase 3/4 inhibitor pumafentrine reduce clinical score and TNF expression in experimental colitis in mice.
Rieder F; Siegmund B; Bundschuh DS; Lehr HA; Endres S; Eigler A
PLoS One; 2013; 8(2):e56867. PubMed ID: 23468885
[TBL] [Abstract][Full Text] [Related]
6. PAN-selective inhibition of cAMP-phosphodiesterase 4 (PDE4) induces gastroparesis in mice.
McDonough W; Aragon IV; Rich J; Murphy JM; Abou Saleh L; Boyd A; Koloteva A; Richter W
FASEB J; 2020 Sep; 34(9):12533-12548. PubMed ID: 32738081
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease.
Lipworth BJ
Lancet; 2005 Jan 8-14; 365(9454):167-75. PubMed ID: 15639300
[TBL] [Abstract][Full Text] [Related]
8. [Progress in PDE4 targeted therapy for inflammatory diseases].
Song SD; Tang HF
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2014 May; 43(3):353-8. PubMed ID: 24998661
[TBL] [Abstract][Full Text] [Related]
9. Novel Roflumilast analogs as soft PDE4 inhibitors.
Boland S; Alen J; Bourin A; Castermans K; Boumans N; Panitti L; Vanormelingen J; Leysen D; Defert O
Bioorg Med Chem Lett; 2014 Sep; 24(18):4594-4597. PubMed ID: 25149511
[TBL] [Abstract][Full Text] [Related]
10. Effects of tadalafil (PDE5 inhibitor) and roflumilast (PDE4 inhibitor) on airway reactivity and markers of inflammation in ovalbumin-induced airway hyperresponsiveness in guinea pigs.
Mokry J; Urbanova A; Medvedova I; Kertys M; Mikolka P; Kosutova P; Mokra D
J Physiol Pharmacol; 2017 Oct; 68(5):721-730. PubMed ID: 29375047
[TBL] [Abstract][Full Text] [Related]
11. Roflumilast, type 4 phosphodiesterase inhibitor, attenuates inflammation in rats with ulcerative colitis via down-regulation of iNOS and elevation of cAMP.
El-Ashmawy NE; Khedr NF; El-Bahrawy HA; El-Adawy SA
Int Immunopharmacol; 2018 Mar; 56():36-42. PubMed ID: 29331766
[TBL] [Abstract][Full Text] [Related]
12. PDE4 inhibition reduces neointima formation and inhibits VCAM-1 expression and histone methylation in an Epac-dependent manner.
Lehrke M; Kahles F; Makowska A; Tilstam PV; Diebold S; Marx J; Stöhr R; Hess K; Endorf EB; Bruemmer D; Marx N; Findeisen HM
J Mol Cell Cardiol; 2015 Apr; 81():23-33. PubMed ID: 25640159
[TBL] [Abstract][Full Text] [Related]
13. The phosphodiesterase-4 inhibitor roflumilast decreases ethanol consumption in C57BL/6J mice.
Liu X; Hao PD; Yang MF; Sun JY; Mao LL; Fan CD; Zhang ZY; Li DW; Yang XY; Sun BL; Zhang HT
Psychopharmacology (Berl); 2017 Aug; 234(16):2409-2419. PubMed ID: 28477089
[TBL] [Abstract][Full Text] [Related]
14. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
[TBL] [Abstract][Full Text] [Related]
15. Current insights on clinical efficacy of roflumilast for treatment of COPD, asthma and ACOS.
Bodkhe S; Nikam M; Sherje AP; Khan T; Suvarna V; Patel K
Int Immunopharmacol; 2020 Nov; 88():106906. PubMed ID: 33182057
[TBL] [Abstract][Full Text] [Related]
16. The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation.
Konrad FM; Bury A; Schick MA; Ngamsri KC; Reutershan J
PLoS One; 2015; 10(4):e0121725. PubMed ID: 25909327
[TBL] [Abstract][Full Text] [Related]
17. Phosphodiesterase 4 inhibitors in inflammatory bowel disease: a comprehensive review.
Salari-Sharif P; Abdollahi M
Curr Pharm Des; 2010; 16(33):3661-7. PubMed ID: 21128899
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of roflumilast and PDE4 inhibitors with a focus on the treatment of asthma.
Al-Sajee D; Yin X; Gauvreau GM
Expert Opin Pharmacother; 2019 Apr; 20(5):609-620. PubMed ID: 30722707
[TBL] [Abstract][Full Text] [Related]
19. The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.
Davis TG; Peterson JJ; Kou JP; Capper-Spudich EA; Ball D; Nials AT; Wiseman J; Solanke YE; Lucas FS; Williamson RA; Ferrari L; Wren P; Knowles RG; Barnette MS; Podolin PL
J Pharmacol Exp Ther; 2009 Sep; 330(3):922-31. PubMed ID: 19498103
[TBL] [Abstract][Full Text] [Related]
20. PDE4 Inhibition as Potential Treatment of Epidermolysis Bullosa Acquisita.
Koga H; Recke A; Vidarsson G; Pas HH; Jonkman MF; Hashimoto T; Kasprick A; Ghorbanalipoor S; Tenor H; Zillikens D; Ludwig RJ
J Invest Dermatol; 2016 Nov; 136(11):2211-2220. PubMed ID: 27388992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
